Drug Trial Radar · NCT06843317
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Mar 21, 2025
Primary completion
Mar 3, 2026
Study completion Jun 3, 2026
Sponsor
- Lead sponsor
- Clover Biopharmaceuticals USA, LLCIndustry
- Sponsor type
- Industry
- First posted
- Feb 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
Conditions
- RSV Infection
Interventions
Candidate vaccine, SCB-1019TBiological
SCB-1019T is a novel bivalent recombinant RSV vaccine (CHO Cell) designed to broadly neutralize the two dominant circulating strains of the virus. The SCB-1019T vaccine consists of the PreF protein subunits from the two dominant circulating strains, strain A and strain B, fused to Trimer-Tag™.
AREXVYBiological
positive comparator
placeboOther
Placebo Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and reactogenicity of revaccination with SCB-1019T vaccineTime frame: Within 7 days after vaccination
- To evaluate the safety and reactogenicity of revaccination with SCB-1019T vaccineTime frame: Within 28 days after vaccination
- To evaluate the safety and reactogenicity of revaccination with SCB-1019T vaccineTime frame: Throughout the study period, from enrollment to 6 months follow up
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
AMR Phoenix
Phoenix, Arizona · Recruiting
AMR Fort Myers
Fort Myers, Florida · Recruiting
AMR Lexington
Lexington, Kentucky · Recruiting
AMR Kansas City
Kansas City, Missouri · Recruiting
Knoxville
Knoxville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.